Sharp Brains: Brain Fitness and Cognitive Health News

Neuroplasticity, Brain Fitness and Cognitive Health News

Icon

An idea gaining traction: Can measuring typing cadence help monitor and treat Parkinson’s Disease?

FDA grants break­through device des­ig­na­tion to Neu­raMetrix (press release):

The U.S. Food and Drug Admin­is­tra­tion (FDA) has grant­ed Break­through Device des­ig­na­tion to the Neu­raMetrix brain health mon­i­tor­ing solu­tion. The des­ig­na­tion is grant­ed for devices “that pro­vide more effec­tive treat­ment or diag­no­sis of life-threat­en­ing or irre­versibly debil­i­tat­ing human dis­ease or con­di­tions”. The approved use is mon­i­tor­ing of Parkinson’s dis­ease (PD) Read the rest of this entry »

Otsuka Pharma and Click Therapeutics enter partnership poised to transform mental healthcare

Otsu­ka, Click Ther­a­peu­tics part­ner to cre­ate ther­a­py for men­tal ill­ness (Ver­dict Med­ical Devices):

Otsu­ka Pharmaceutical’s US divi­sion Otsu­ka Amer­i­ca has part­nered with Click Ther­a­peu­tics to devel­op and com­mer­cialise a pre­scrip­tion dig­i­tal ther­a­peu­tic for treat­ing major depres­sive dis­or­der (MDD) Read the rest of this entry »

FDA clears deep transcranial magnetic stimulation device to treat obsessive-compulsive disorder

___

BrainsWay’s Brain Stim­u­la­tion Device Receives FDA Approval to Treat Obses­sive-Com­pul­sive Dis­or­der (IEEE Spec­trum):

In 2013, Jerusalem-based Brain­sWay began mar­ket­ing a new type of brain stim­u­la­tion device that uses mag­net­ic puls­es to treat major depres­sive dis­or­der.

Now, thanks to pos­i­tive results in a study of 100 patients, the com­pa­ny has received approval from the U.S. Food and Drug Admin­is­tra­tion (FDA) to mar­ket the device for a sec­ond psy­chi­atric condition—obsessive-compulsive dis­or­der (OCD) Read the rest of this entry »

Update: 200 common prescription medications increase depression risk

___

Dear read­er,

Time for Sharp­Brains e-newslet­ter.

It’s been a busy month, once again bring­ing to the fore­front the lim­i­ta­tions of our cur­rent health­care sys­tem and, on the pos­i­tive side, the grow­ing oppor­tu­ni­ties to improve Brain Health and Men­tal Health for all, if we pay atten­tion to (and act on) lat­est research, think­ing and tools.

New tools:

 

Final­ly, we invite you to tease your mind with these four opti­cal illu­sions. Sur­pris­ing, aren’t they?

Have a great month of July,

 

The Sharp­Brains Team

FDA clears MindMaze GO neurorehabilitation platform, easing access to continued outpatient therapy

___

Mind­Maze Con­sol­i­dates First-ever FDA Approval for Inpa­tient and Out­pa­tient Neu­rore­ha­bil­i­ta­tion Ther­a­py (press release):

Mind­Maze, a leader in brain­tech, has today announced that it has obtained FDA clear­ance to launch its portable neu­rore­ha­bil­i­ta­tion prod­uct, Mind­Mo­tion™ GO, in the Unit­ed States. Togeth­er with Mind­Mo­tion PRO (which received FDA clear­ance in 2017), Mind­Mo­tion GO is the next offer­ing in the company’s con­tin­u­um of care, pro­vid­ing gam­i­fied neu­rore­ha­bil­i­ta­tion ther­a­py. Read the rest of this entry »

About SharpBrains

As seen in The New York Times, The Wall Street Journal, BBC News, CNN, Reuters and more, SharpBrains is an independent market research firm tracking health and performance applications of brain science.

Follow us and Engage via…

twitter_logo_header
RSS Feed

Search for anything brain-related in our article archives

Enter Your Email to receive Sharp­Brains free, monthly eNewslet­ter:

Join more than 50,000 Sub­scribers and stay informed and engaged.